ESC TV Today – Your Cardiovascular News Episode 14: Among the topics: ICD indications in 2023 - The diagnostic workup of cardiac amyloidosis
ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly.
This episode covers:
Cardiology This Week: A concise summary of recent studies
Indications for ICD treatment: Current standards and new developments
The diagnostic workup of cardiac amyloidosis
Diagnostics Made Easy - Ventricular tachycardia
Host: Susanna Price
Guests: Davide Capodanno, Martha Grogan, Gerhard Hindricks and Emma Svennberg
Want to watch that episode?
Go to: https://esc365.escardio.org/event/1029
Disclaimer
This programme is intended for health care professionals only and is to be used for educational purposes.
The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices.
Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.
Declarations of interests
Stephan Achenbach, Gerhard Hindricks, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report.
Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede.
Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi, Daiichi Sankyo, Terumo, Medtronic, Chiesi.
Martha Grogan has declared to have potential conflicts of interest to report: consultancy – Janssen, NovoNordisk. Research grant, or contract – Alnylam, Eidos, Janssen, Pfizer, NovoNordisk. Patent – Anumana. All Disclosures: no personal compensation, all funds to Mayo Clinic
Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer- Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.